Skip to content

Study on the interaction between barley beta-glucan and pharmaceutical products

Study on the interaction between barley beta-glucan and pharmaceutical products - Study on the interaction between barley beta-glucan and pharmaceutical products

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000028623
Enrollment
30
Registered
2017-08-10
Start date
2017-08-11
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Diet and exercise therapy group The first day(D0), doctor&#39
s hearing, meal tolerance test and installation of CGM are implemented. During a ingestion period, ingest 2 packs of white rice a day (D1 to D5), then ingest 2 packs of barley mixed rice a day (D6 to

Sponsors

Nakakinen Clinic Medical corporation kensei-kai
Lead Sponsor
Faculty of Life and Environmental Sciences,University of Yamanashi
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Type 2 diabetic patients who satisfy one of the following conditions. A) Those who are treated with diet / exercise only. B) In addition to diet / exercise therapy, those taking alpha-GI (acarbose). C) In addition to diet / exercise therapy, those taking metformin. Those taking acarbose or metformin should not change the dosage more than 60 days before D0. (2) Persons whose HbA1c are 6.5 to 8.5% (when obtaining consent). (3) Persons who are over 20 years old. (4) Persons who obtained consent.

Exclusion criteria

Exclusion criteria: (1) Serious ketosis, diabetic coma or precoma, patients with dialysis and type 1 diabetic patients. (2) Patients with diseases or trauma such as serious infection, before and after surgery, cancer, etc. (3) Those who are taking hypoglycemic drugs except the drugs listed in the selection criteria. (4) Persons who merged gastrointestinal disorders affecting digestion / absorption. (5) Persons who have a medical history of gastrointestinal resection. (6) Persons who merged serious liver and kidney problems (as judged by a doctor). (7) Persons who developed myocardial infarction / stroke within 180 days before D0. (8) Persons who take systemic steroids (excluding local). (9) Smokers. (10) Persons who are drinking excessively (For example, 180 mL or more of sake per day, three or more big bottles of beer per day). (11) Persons who have a history of hypersensitivity (food allergy etc.) to the test meals (barley, rice, wheat, milk ingredients, apples, beef, pork, soybeans and sesame). (12) Persons who usually consume barley. (13) Pregnant women or ladies who may be pregnant. (14) Others who are judged inappropriate by the representative doctor.

Design outcomes

Primary

MeasureTime frame
Blood glucose (0, 30, 60, 90, 120 min)

Secondary

MeasureTime frame
CGM Data Insulin (0, 30, 60, 90, 120 min) Inflammation related factor (0, 120 min) Incretin (0, 30, 60, 120 min) Feeding hormone (0, 30, 60, 120 min) Safety data: Weight, BMI Blood pressure measurement General biochemical test Blood cell test Questionnaire: Advance questionnaire Questionnaire(Test day) Diet survey form

Countries

Japan

Contacts

Public ContactKensuke Ofuchi

Nakakinen Clinic Medical corporation kensei-kai Department of clinical research

k-ofuchi@kensei-kai.com029-353-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026